LLY241018P975000
- 48.00
- -13.50-21.95%
Eli Lilly and Co Newsroom
The good news for the obese population in the USA: FDA is considering allowing the combination version of eli lilly and co (LLY.US) weight loss drug.
(FDA) agreed on Friday to reconsider the decision made last month, which banned private drug compounders from selling their own compounded versions of eli lilly and co's weight loss and diabetes treatment drugs.
Express News | UK's Department of Health and Social Care: £279 Mln From 'eli Lilly and Company' as Part of Collaboration
Express News | UK's Department of Health and Social Care: Memorandum of Understanding Signed Between Hmg & Eli Lilly to Back UK Life Sciences
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,025
Eli Lilly and Co (LLY.US) CEO: Its Alzheimer's drugs can play a "preventive" role.
Eli Lilly and Co's CEO told the United Kingdom Health Minister that their method of treating Alzheimer's disease can 'prevent' the disease.
Futu Morning Post | Hong Kong stocks heavy! Hong Kong Chief Executive John Lee Ka-chiu will deliver her third policy address in office; Can Nvidia reach a new high? Morgan Stanley reveals: Blackwell's future one-year supply has been sold out.
The Ministry of Finance has released an important signal! It will introduce a package of incremental policy measures; the first china stocks etf's net assets have exceeded one hundred billion, overseas institutions emphasize the undiminished valuation advantages; the stock buyback trend in the Hong Kong stock market continues! Tencent is expected to complete the billion-dollar buyback ahead of schedule.
Eli Lilly CEO Told UK Health Secretary Its Alzheimer's Treatment Could "Prevent" Disease: FT
Weight Loss Drugs Have One Big Issue; These Companies Want to Fix It
Boasting A 54% Return On Equity, Is Eli Lilly and Company (NYSE:LLY) A Top Quality Stock?
Eli Lilly and Company (LLY): Among the Most Promising Growth Stocks According to Hedge Funds
Streetwise: Snack Slump Hits Big Food. Blame Prices, Not Obesity Meds. -- Barron's
US stocks closed: on the two-year anniversary of this bull market, the S&P and Dow hit new highs, while Chinese stocks collectively strengthened.
①The s&p 500 index welcomes the second anniversary of the bull market, and on Friday, for the first time in history, it stood above the 5800 point integer mark; ②The nasdaq China Golden Dragon Index has risen for two consecutive days; ③Tesla fell by 8%, while uber technologies and Lyft strengthened; ④Boeing announced a 10% workforce reduction.
Express News | US FDA Seeks to Reconsider Decision Preventing Drug Compounders From Selling Versions of Lilly's Weight Loss, Diabetes Drugs
Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market
Criminal Networks Cash In On Demand For Weight Loss Drugs, Authorities Say
U.S. stocks are on the move | The weight loss drug Zepbound is expected to be approved in japan next year, eli lilly (LLY.US) rose more than 1%.
On Friday, eli lilly and co (LLY.US) stock price fluctuated upwards, rising 1.18% as of press time, to $921.435.
Eli Lilly and Co CEO: Weight loss drug Zepbound is expected to be approved in Japan next year.
October 11, Guronghui | eli lilly and co CEO said on Friday that the weight loss drug Zepbound is expected to be approved in Japan next year.
Street Color: Eli Lilly's Zepbound Expected to Receive Japan Approval in 2025, Nikkei Asia Reports
Express News | Market news: eli lilly and co officials stated that the Japanese government is expected to approve the company's popular obesity treatment drug Zepbound in the coming months.
Express News | Japanese Government on Track to Approve of Eli Lilly's Popular Obesity Treatment Zepbound in Coming Months, Head of Co Says - Nikkei